Relmada Therapeutics Presents Initial P-II Trial Data of NDV-01 for High-Grade Non-Muscle Invasive Bladder Cancer (HG-NMIBC) at AUA 2025
Shots:
- Relmada has reported initial P-II trial data assessing NDV-01 in 20 pts with HG-NMIBC (8 BCG-naïve, 12 BCG-unresponsive), where 2 pts had CIS & 18 had papillary disease (Ta/T1); 26 pts are enrolled, with 20 reaching 3mos. & 7 reaching 6mos. assessments
- Trial showed 85% ORR, 83.3% HGRFS in Ta/T1, & 100% CR in CIS pts at 3mos.; 90% ORR, 88.8% HGRFS in Ta/T1, & 100% CR in CIS at any time, with all 7 evaluable pts (1 CIS & 6 Ta/T1) achieving disease-free status, incl. 1 of these, who was re-treated at 3mos
- NDV-01 is an intravesical formulation of gemcitabine & docetaxel that forms a soft matrix in the bladder, allowing 10-day drug release without anesthesia or special equipment, with patent protection through 2038
Ref: GlobeNewswire | Image: Relmada Therapeutics
Related News:- Relmada Therapeutics Reported Results for REL-1017 in the P-III Trial for the Treatment of Major Depressive Disorders
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
